Project Bioshield:

Actions Needed to Avoid Repeating Past Problems with Procuring New Anthrax Vaccine and Managing the Stockpile of Licensed Vaccine

GAO-08-88: Published: Oct 23, 2007. Publicly Released: Oct 23, 2007.

Additional Materials:

Contact:

Keith A. Rhodes
(202) 512-6412
contact@gao.gov

 

Office of Public Affairs
(202) 512-4800
youngc1@gao.gov

The anthrax attacks in September and October 2001 highlighted the need to develop medical countermeasures. The Project BioShield Act of 2004 authorized the Department of Health and Human Services (HHS) to procure countermeasures for a Strategic National Stockpile. However, in December 2006, HHS terminated the contract for a recombinant protective antigen (rPA) anthrax vaccine because VaxGen failed to meet a critical contractual milestone. Also, supplies of the licensed BioThrax anthrax vaccine already in the stockpile will start expiring in 2008. GAO was asked to identify (1) factors contributing to the failure of the rPA vaccine contract and (2) issues associated with using the BioThrax in the stockpile. GAO interviewed agency and industry officials, reviewed documents, and consulted with biodefense experts.

Three major factors contributed to the failure of the first Project BioShield procurement effort for an rPA anthrax vaccine. First, HHS's Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded the procurement contract to VaxGen, a small biotechnology firm, while VaxGen was still in the early stages of developing a vaccine and had not addressed many critical manufacturing issues. This award preempted critical development work on the vaccine. Also, the contract required VaxGen to deliver 25 million doses of the vaccine in 2 years, which would have been unrealistic even for a larger manufacturer. Second, VaxGen took unrealistic risks in accepting the contract terms. VaxGen officials told GAO that they accepted the contract despite significant risks due to (1) the aggressive delivery time line for the vaccine, (2) VaxGen's lack of in-house technical expertise--a condition exacerbated by the attrition of key company staff as the contract progressed--and (3) VaxGen's limited options for securing any additional funding needed. Third, important Food and Drug Administration (FDA) requirements regarding the type of data and testing required for the rPA anthrax vaccine to be eligible for use in an emergency were not known at the outset of the procurement contract. In addition, ASPR's anticipated use of the rPA anthrax vaccine was not articulated to all parties clearly enough and evolved over time. Finally, according to VaxGen, the purchase of BioThrax for the stockpile as a stopgap measure raised the bar for the VaxGen vaccine. All these factors created confusion over the acceptance criteria for VaxGen's product and significantly diminished VaxGen's ability to meet contract time lines. ASPR has announced its intention to issue another request for proposal for an rPA anthrax vaccine procurement but, along with other HHS components, has not analyzed lessons learned from the first contract's failure and may repeat earlier mistakes. According to industry experts, the lack of specific requirements is a cause of concern to the biotechnology companies that have invested significant resources in trying to meet government needs and now question whether the government can clearly define future procurement contract requirements. GAO identified two issues related with the use of the BioThrax in the Strategic National Stockpile. First, ASPR lacks an effective strategy to minimize the waste of BioThrax. Starting in 2008, several lots of BioThrax in the Strategic National Stockpile will begin to expire. As a result, over $100 million per year could be lost for the life of the vaccine currently in the stockpile. ASPR could minimize such potential waste by developing a single inventory system with Department of Defense (DOD)--a high-volume user of BioThrax--with rotation based on a first-in, first-out principle. DOD and ASPR officials identified a number of obstacles to this type of rotation which may require legislative action. Second, ASPR planned to use three lots of expired BioThrax vaccine in the stockpile in the event of an emergency. This would violate FDA rules, which prohibit using an expired vaccine, and could also undermine public confidence because the vaccine's potency could not be guaranteed.

Recommendations for Executive Action

  1. Status: Open

    Comments: When we confirm what actions the agency has taken in response to this recommendation, we will provide updated information.

    Recommendation: To avoid repeating the mistakes that led to the failure of the first rPA procurement effort, the Secretary of HHS should direct ASPR, National Institute of Allergy and Infectious Diseases, FDA, and Centers for Disease Control and Prevention to ensure that the concept of use and all critical requirements are clearly articulated at the outset for any future medical countermeasure procurement.

    Agency Affected: Department of Health and Human Services

  2. Status: Open

    Comments: When we confirm what actions the agency has taken in response to this recommendation, we will provide updated information.

    Recommendation: To ensure public confidence and comply with FDA's current rules, the Secretary of HHS should direct ASPR to destroy the expired BioThrax vaccine in the stockpile.

    Agency Affected: Department of Health and Human Services

  3. Status: Closed - Implemented

    Comments: On March 11, 2008, DOD and the DHHS's CDC have signed an Interagency Agreement(IAA)which establishes a framework for the acquisition, storage, management, and delievery of anthrax vaccine from the Strategic National Stockpile to meet DOD's operational and inventory requirements for anthrax vaccine. This IAA implements GAO Report recommendation for a single DOD-DHHS inventory management system based on first-in, first-out principle to reduce wastage.

    Recommendation: To minimize waste of the BioThrax vaccine in the stockpile, the Secretaries of HHS and the Department of Defense should develop a single integrated inventory system for the licensed anthrax vaccine, with rotation based on a first-in, first-out principle.

    Agency Affected: Department of Health and Human Services

  4. Status: Closed - Implemented

    Comments: On March 11, 2008, DOD and DHHS's CDC signed an Interagency Agreement (IAA) which established a framework for the acquisition, storage, management, and delivery of anthrax vaccine adsorbed from the Strategic National Stockpile to meet DOD's operational and inventory requirement for anthrax vaccine. This implements GAO's report 08-88 recommendation for a single DOD-DHHS inventory management system based on first-in, first-out principle to reduce wastage.

    Recommendation: To minimize waste of the BioThrax vaccine in the stockpile, the Secretaries of HHS and the Department of Defense should develop a single integrated inventory system for the licensed anthrax vaccine, with rotation based on a first-in, first-out principle.

    Agency Affected: Department of Defense

 

Explore the full database of GAO's Open Recommendations »

Oct 29, 2014

Oct 6, 2014

Oct 2, 2014

Sep 29, 2014

Sep 23, 2014

Sep 18, 2014

Sep 16, 2014

Sep 9, 2014

Looking for more? Browse all our products here